fluorodeoxyglucose f18 has been researched along with Minimal Disease, Residual in 244 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 29 (11.89) | 18.2507 |
| 2000's | 106 (43.44) | 29.6817 |
| 2010's | 86 (35.25) | 24.3611 |
| 2020's | 23 (9.43) | 2.80 |
| Authors | Studies |
|---|---|
| Boormans, JL; Hinsenveld, FJ; Noordman, BJ; Oprea-Lager, DE; van Beek, SC; van der Pas, SL; van Leenders, GJLH; Vis, AN; Voortman, J | 1 |
| Alapat, D; Baker, D; Bimali, M; Carrillo, L; Erra, A; Gundarlapalli, S; Hoque, MS; Kottarathara, M; Mathur, P; Mitma, AA; Ogunsesan, Y; Parikh, R; Sachedina, A; Schinke, C; Thanendrarajan, S; Tricot, G; Van Rhee, F; Yarlagadda, L; Zangari, M | 1 |
| Alberge, JB; Avet-Loiseau, H; Bailly, C; Béné, MC; Bodet-Milin, C; Caillon, H; Carlier, T; Chérel, M; Corre, J; Jamet, B; Kampfenkel, T; Kraeber-Bodéré, F; Magrangeas, F; Minvielle, S; Moreau, P; Sonneveld, P; Touzeau, C; van Duin, M; Wuilleme, S | 1 |
| Matsue, K; Terao, T | 1 |
| Akashi, K; Baba, S; Iawasaki, H; Ishigami, K; Kamesaki, K; Kato, K; Kikushige, Y; Kunisaki, Y; Miyamoto, T; Miyawaki, K; Mori, Y; Numata, A; Shima, T; Sugio, T; Takashima, S; Takenaka, K; Urata, S; Yoshimoto, G | 1 |
| Arangio Febbo, M; Barilà, G; Cabrelle, G; Campi, C; Cecchin, D; Crimì, F; Lacognata, C; Pavan, L; Semenzato, G; Vedovato, S; Zambello, R; Zanon, C; Zucchetta, P | 1 |
| Aftandilian, C; Baggott, C; Davis, KL; Erickson, C; Lacayo, N; Mackall, CL; Nadel, HR; Oak, J; Ramakrishna, S; Schultz, L; Walkush, A | 1 |
| Aro, K; Atula, T; Ilmarinen, T; Markkola, A; Schildt, J; Sistonen, HJ | 1 |
| Ito, J; Iwabuchi, Y; Nakazawa, A; Shima, H; Shimada, H; Takaki, T | 1 |
| Jain, A; Naumani, SP; Riyami, KA; Shamim, MS; Sukaiti, RA; Usman, S | 1 |
| Bailly, C; Bodet-Milin, C; Carlier, T; Frecon, G; Kraeber-Bodere, F; Le Gouill, S; Macintyre, E; Morvant, C; Safar, V; Tournilhac, O | 1 |
| Mottet, N; Tremeau, L | 1 |
| Dimitrakopoulou-Strauss, A; Goldschmidt, H; Sachpekidis, C | 1 |
| Siegel, C | 1 |
| Landgren, CO; Ulaner, GA | 1 |
| Du, G; Fu, Z; Liu, L; Xue, M | 1 |
| Dorgelo, B; Fazzi, M; Hanemaaijer, SH; Oosting, SF; Plaat, BEC; Steenbakkers, RJHM; Stormezand, GN; van der Laan, BFAM; van der Vegt, B; Witjes, MJH | 1 |
| Chung, YS; Kang, WJ; Kim, HS; Kim, S; Kim, SW; Kim, YT; Lee, JY; Nam, EJ | 1 |
| Ahmed, G; El Semary, SF; Kenaai, NE; Nagy, N; Omar, W; Rahman, HA; Zaky, I | 1 |
| Ackermans, LL; Beets-Tan, RG; Griethuysen, JJV; Lambregts, DM; Maas, M; Min, LA; Nowee, ME; Roberti, S; Vogel, WV | 1 |
| Bailly, C; Bodet-Milin, C; Carlier, T; Jamet, B; Kraeber-Bodere, F; Michaud, AV; Moreau, P; Nanni, C; Touzeau, C; Zamagni, E | 1 |
| Bailly, C; Barbato, S; Boccadoro, M; Bodet-Milin, C; Caillot, D; Carlier, T; Cavo, M; Chauvie, S; Dozza, L; Fanti, S; Gallamini, A; Gamberi, B; Garderet, L; Gay, F; Karlin, L; Kraeber-Bodéré, F; Macro, M; Moreau, P; Nanni, C; Patriarca, F; Perrot, A; Sonneveld, P; Tacchetti, P; Versari, A; Zamagni, E | 1 |
| Acid, S; Gheysens, O; Hillengass, J; Jamar, F; Kirchgesner, T; Lecouvet, FE; Malghem, J; Van Den Berghe, T; Vande Berg, BC; Vandecaveye, V; Vekemans, MC; Verstraete, K; Wuts, J | 1 |
| Castelijns, JA; de Bree, R; de Graaf, P; de Jong, MC; Hoekstra, OS; Jagesar, VA; Noij, DP | 1 |
| Carp, L; Helsen, N; Roothans, D; Stroobants, S; Van Den Heuvel, B; Van den Weyngaert, D; Van den Wyngaert, T | 1 |
| Arnous, MMR; Hu, F; Lan, X; Qin, C | 1 |
| Ahn, TS; Baek, MJ; Lee, JW; Lee, SM | 1 |
| Emi, A; Goda, N; Kadoya, T; Kajitani, K; Masumoto, N; Okada, M; Sasada, S | 1 |
| Barlogie, B; Davies, FE; Hoering, A; McDonald, JE; Morgan, GJ; Ntambi, JA; Panozzo, SB; Petty, NM; Rasche, L; Rosenthal, A; Schinke, CD; Steward, DM; Thanendrarajan, S; van Rhee, F; Walker, B; Weinhold, N; Zangari, M | 1 |
| Becker, S; Berriolo-Riedinger, A; Casasnovas, O; Édeline, V; Vander Borght, T | 1 |
| Chang, SK; Jeong, Y; Jung, IH; Kim, JS; Lee, SW | 1 |
| Bai, X; Wang, X | 1 |
| Hoogendam, JP; Roze, JF; Scholten, RJ; Spijker, R; van de Wetering, FT; Veldhuis, WB; Verleye, L; Vlayen, J; Zweemer, RP | 1 |
| Cortés-Romera, M; Cos-Domingo, M; Gámez Cenzano, C; Moreno-Llorente, P; Pérez-Maraver, M; Reynés-Llompart, G; Rodríguez-Bel, L; Rossi-Seoane, S; Sabaté-Llobera, A; Vercher Conejero, JL | 1 |
| Al-Mamgani, A; de Ridder, M; Gouw, ZAR; Hamming-Vrieze, O; Jasperse, B; Navran, A; van den Brekel, MWM; Vogel, WV | 1 |
| Anconina, R; Hod, N; Lantsberg, S; Levi, I; Levin, D; Nalbandyan, K | 1 |
| Eyck, BM; Lagarde, SM; Nieboer, D; Noordman, BJ; Onstenk, BD; Spaander, MCW; Valkema, R; van Lanschot, JJB; Wijnhoven, BPL | 1 |
| Hao, C; Lu, SJ; Seet, JE; Sinha, A; Wong, AS | 1 |
| Ishii, K; Kuroda, H; Matsuki, M; Murakami, T; Okada, M; Tsurusaki, M | 1 |
| Böll, B; Eich, HT; Engert, A; Klimm, B; Kriz, J; Müller, RP; Rancea, M; Schmidberger, H | 1 |
| de Bree, R; Ferlito, A; Rinaldo, A; Takes, RP; Zbären, P | 1 |
| Peggs, KS; Thomson, KJ | 1 |
| Bellò, M; Bisi, G; Caracciolo, D; Chiappella, A; Douroukas, A; Filippi, AR; Giunta, F; Piva, C; Ragona, R; Ricardi, U; Vitolo, U; Zotta, M | 1 |
| Ekmekcioglu, O; Elicin, O; Halac, M; Uzel, EK; Uzel, OE | 1 |
| Capirci, C; Chondrogiannis, S; Colletti, PM; Ferretti, A; Grassetto, G; Maffione, AM; Marzola, MC; Rampin, L; Rubello, D | 1 |
| Choi, H; Kim, DY; Kim, SK; Kim, TS; Oh, JH; Yoon, HJ | 1 |
| Chang, ZH; Guo, QY; Han, CB; Liu, ZY; Lu, ZM; Ma, JT; Zheng, JH | 1 |
| Borbély, K; Géczi, L; Kásler, M | 1 |
| Bilen, MA; Guo, CC; Hariri, H; Kuban, DA; Leon, C; Pisters, LL; Tu, SM | 1 |
| Almquist, H; Brun, E; Kjellén, E; Sjövall, J; Wahlberg, P | 1 |
| Berlangieri, S; Eek, R; Murphy, C; Schwalb, H | 1 |
| Buvat, I; Chouahnia, K; Cyrta, J; Eder, V; Martinod, E; Morère, JF; Orlhac, F; Pouliquen, C; Soussan, M | 1 |
| Li, F; Wang, R; Xiao, J; Xing, B; Zhao, X; Zhu, Z | 1 |
| Belsack, D; Buls, N; de Mey, J; Everaert, H; Ilsen, B; Ros, PR; Vandemeulebroucke, J; Vandenbroucke, F; Verdries, D | 1 |
| Demir, N; Demirkol, MO; Tokmak, H | 1 |
| Bae, SK; Jung, SJ; Kim, CK; Kim, TH; Lee, SM; Park, JS; Yoon, HK | 1 |
| Anelli, V; Covello, R; Kayal, R; Manciocco, V; Marucci, L; Mercante, G; Pellini, R; Pichi, B; Sanguineti, G; Sciuto, R; Sperduti, I; Spriano, G; Turri-Zanoni, M; Vidiri, A | 1 |
| Das, M; Fontanarosa, D; Spijkerman, J; Van Elmpt, W | 1 |
| Adalet, I; Aral, F; Gecer, MF; Kuyumcu, S; Ozel, S; Ozkan, ZG; Uzum, AK | 1 |
| Bhojwani, D; Choi, JK; Davidoff, AM; Gold, R; Inaba, H; McCarville, MB; Metzger, ML; Sandlund, JT; Sawyer, J; Shulkin, BL | 1 |
| El-Rabadi, K; Georgios, K; Karanikas, G; Karem, el-R; Knogler, T; Marius Erik, M; Mayerhoefer, ME; Michael, W; Thomas, K; Weber, M | 1 |
| Hoh, CK; Hoshi, H; Kanematsu, M; Kesari, S; Nozawa, A; Piccioni, D; Rivandi, AH | 1 |
| Baues, C; Dietlein, M; Eich, HT; Engenhart-Cabillic, R; Engert, A; Haverkamp, H; Haverkamp, U; Hegerfeld, K; Herfarth, K; Kobe, C; Kriz, J; Kuhnert, G; Lukas, P; Reinartz, G; Schmidberger, H; Staar, S | 1 |
| Chen, L; Hu, W; Wang, Y; Wei, G; Xian, W; Zhang, N | 1 |
| Arisaka, O; Fukushima, K; Hashimoto, T; Kurosawa, H; Kuwashima, S; Okamoto, K; Sakamoto, S; Sato, Y; Tsuchioka, T | 1 |
| Castetbon, V; de Clermont-Galleran, H; de Monès, E; Digue, L; Fernandez, P; Ghafouri, A; Haaser, T; Sagardoy, T | 1 |
| Anastasia, A; Biasoli, I; Federico, M; Ferrari, A; Galimberti, S; Luminari, S; Manni, M; Petrini, M; Rusconi, C; Versari, A | 1 |
| Cai, H; Li, L; Shen, G; Zhang, W; Zhou, H; Zhou, Y | 1 |
| Abdelhafez, YG; El Refaei, S; Hamada, E; Osama, A; Tawakol, A | 1 |
| Adams, HJ; Kwee, TC | 1 |
| Ahn, SG; Choi, SE; Jeong, J; Jung, WH; Lee, HM; Lee, HW; Lee, MK; Yoo, H | 1 |
| Ben Taylor, M; Bishton, MJ; Bloor, AJC; Chakraverty, R; Fielding, AK; Fox, CP; Kayani, I; Mackinnon, S; Morris, EC; Peggs, KS; Reyal, Y; Russell, N; Sjursen, AM; Thomson, KJ | 1 |
| Ferraro, R; Marcus, C; Rahmim, A; Sheikhbahaei, S; Subramaniam, RM; Wray, R; Zan, E | 1 |
| Burkill, GJ; Dizdarevic, S; Gilbert, DC; Jones, JR; McKinna, F; Teagle, AR | 1 |
| Chen, WW; Cheng, MF; Chou, YH; Ko, KY; Yen, RF | 1 |
| Hashizume, A; Kawai, M; Kishida, T; Mizuno, N | 1 |
| Balzarotti, M; Cabrera, ME; Ceriani, L; Chiappella, A; Cunningham, D; Ferreri, AJ; Giovanella, L; Gospodarowicz, MK; Guarini, A; Johnson, PW; Martelli, M; Ricardi, U; Stelitano, C; Zinzani, PL; Zucca, E | 1 |
| Haresh, KP; Julka, PK; Prabhakar, R; Rath, GK; Sharma, DN; Subramani, V | 1 |
| Doki, Y; Fujiwara, Y; Fukunaga, H; Hatazawa, J; Higuchi, I; Miyata, H; Monden, M; Takiguchi, S; Tatsumi, M; Yano, M; Yasuda, T | 1 |
| Hoshikawa, H; Mitani, T; Mori, N; Nishiyama, Y; Ohkawa, M; Yamamoto, Y | 1 |
| Cammilleri, S; Colavolpe, C; Coze, C; Guedj, E; Mundler, O; Taïeb, D | 1 |
| Balestreri, L; Borsatti, E; Cimitan, M; Comoretto, M; Franchin, G; Lise, M | 1 |
| Alavi, A; Basu, S; Cermik, TF; Dhuriraj, T; Kumar, R; Mavi, A; Torigian, D; Urhan, M; Wasik, M | 1 |
| Amthauer, H; Bares, R; Bockisch, A; Borchmann, P; Diehl, V; Dietlein, M; Eich, HT; Engert, A; Franklin, J; Fuchs, M; Klutmann, S; Knapp, WH; Kobe, C; Lohri, A; Lorenz, R; Markova, J; Mueller, RP; Schicha, H; Schreckenberger, M; Weckesser, M; Zijlstra, JM | 1 |
| Gill, S; Hicks, RJ; Seymour, JF | 1 |
| Brepoels, L; De Wever, W; De Wolf-Peeters, C; Dierickx, D; Mortelmans, L; Stroobants, S; Thomas, J; Vandenberghe, P; Verhoef, G | 1 |
| Chao, M; Drummond, E; Heriot, A; Hicks, RJ; Kalff, V; Ware, R | 1 |
| Agrawal, A; Hall, NC; Martin, EW; Povoski, SP; Ringel, MD | 1 |
| Ahn, JS; Bom, HS; Cho, SH; Chung, IJ; Jeong, YY; Kim, HJ; Kim, YK; Lee, JJ; Min, JJ; Yang, DH | 1 |
| Bares, R; Bokemeyer, C; Brenner, W; de Wit, M; Franzius, C; Hartmann, M; Heicappell, R; Kliesch, S; Krege, S; Mueller, S; Oechsle, K; Venz, S; Weissbach, L | 1 |
| Jain, MK; Spratt, SE; Wong, TZ | 1 |
| Chang, B; Murphy, JJ; Nadel, H; Tawfeeq, M | 1 |
| Ajani, JA; Bhutani, MS; Hofstetter, W; Javeri, H; Komaki, R; Lee, JH; Maru, D; Rohren, E; Swisher, SG; Wang, X; Xiao, L | 1 |
| Auperin, A; Bournaud, C; Busaidy, NL; Corone, C; Ewertz, ME; Jacene, HA; Ladenson, PW; Leboulleux, S; Schlumberger, M; Schroeder, PR; Sherman, SI; Wahl, RL | 1 |
| Herbertson, RA; Lee, ST; Scarsbrook, AF; Scott, AM; Tebbutt, N | 1 |
| Dunn, J; Fisher, S; MacCabe, C; MacLennan, K; Mehanna, H; Nutting, C; Wong, WL | 1 |
| Fields, R; McWhorter, A; Mercante, DE; Nuss, D; Pou, AM; Rabalais, AG; Walvekar, R; Wood, C | 1 |
| Chioléro, R; Duchosal, MA; Pascual, M; Pilon, N; Prior, JO; Schmidt, S; Turini, P | 1 |
| Bourre, JC; Vuillez, JP | 1 |
| Mercier, G; Peller, P; Sakai, O; Subramaniam, RM; Truong, M | 1 |
| Avril, N; Avril-Sassen, S; Dose-Schwarz, J; Jänicke, F; Lebeau, A; Mahner, S; Schwaiger, M; Tiling, R; Untch, M; Weber, C | 1 |
| Bernardi, A; Cacciari, N; Fanti, S; Martoni, AA; Musto, A; Quercia, S; Rosati, M; Santini, D; Taffurelli, M; Zamagni, C | 1 |
| Hyodo, M; Kasahara, N; Koizumi, M; Morishima, K; Sakuma, Y; Sasanuma, H; Sata, N; Shimizu, A; Yasuda, Y | 1 |
| Christodoulou, M; Doenz, F; Gengler, C; Letovanec, I; Orcurto, V; Petermann, D; Prior, JO; Ris, HB | 1 |
| Cabrera, AR; Chen, L; Han, A; Han, D; Li, Y; Ma, L; Ma, Y; Mu, D; Sun, X; Teng, X; Yu, J; Yue, J; Zhao, S; Zhao, X; Zheng, F; Zheng, J | 1 |
| Chan, SC; Chang, JT; Chang, KP; Ko, SF; Liao, CT; Lin, CY; Lin, YC; Ng, SH; Wang, HM; Yen, TC | 1 |
| Cameron, D; Fleming, IN; Gilbert, FJ; Miles, KA | 1 |
| Chen, YK; Hsieh, TC; Kao, CH; Liang, JA; Lin, YY; Sun, SS; Wang, CH; Wu, YC; Yen, KY | 1 |
| Berthelsen, AK; Engelholm, SA; Høgdall, C; Høgdall, E; Loft, A; Lundvall, L; Nedergaard, L; Risum, S | 1 |
| Aerts, HJ; De Ruysscher, D; Lambin, P; Oberije, C; Velazquez, ER | 1 |
| Aide, N; Bohn, P; Briand, M; Carreiras, F; Chasle, J; Deslandes, E; Dutoit, S; Lasnon, C; Modzelewski, R; Poulain, L; Rouvet, J; Vela, A; Vera, P | 1 |
| Klaeser, B; Krause, T | 1 |
| Blumin, J; Campbell, BH; Maheshwari, M; Massey, BL; Michel, MA; Schultz, CJ; Wang, D; Wilson, JF; Wong, SJ; Zundel, MT | 1 |
| Graham, MM; Menda, Y | 1 |
| Cho, KJ; Choi, SH; Kim, JS; Kim, SB; Kim, SY; Lee, JH; Lee, SW; Nam, SY; Roh, JL; Yi, JS | 1 |
| Beadsmoore, C; Geropantas, K; Loo, SW; Martin, WM; Montgomery, PQ; Roques, TW | 1 |
| Buijsen, J; Janssen, MH; Janssens, G; Lambin, P; Lammering, G; Ollers, MC; Reniers, B; van den Bogaard, J | 1 |
| Corry, J; Ferlito, A; Grégoire, V; Hamoir, M; Hanin, FX; Machiels, JP; Rinaldo, A; Robbins, KT; Schmitz, S; Silver, CE; Strojan, P; Takes, RP; Thariat, J; Weynand, B | 1 |
| Ayuk, F; Derlin, T; Habermann, CR; Herrmann, J; Klutmann, S; Kröger, N; Weber, C; Wisotzki, C; Wolschke, C | 1 |
| Hanada, S; Kashima, K; Mataki, H; Nomoto, M; Sonoda, M; Yamashita, E; Yotsumoto, G | 1 |
| Chen, IH; Fan, KH; Hsueh, C; Huang, SF; Kang, CJ; Lee, LY; Liao, CT; Lin, CH; Lin, CY; Ng, SH; Wang, HM; Yen, TC | 1 |
| Imamura, F; Ishikawa, J; Kusakabe, S; Masaie, H; Sugimoto, N; Takahashi, M; Yagi, T; Yamashita, Y; Yoshida, H; Yoshinami, T | 1 |
| Abrahamova, J; Buchler, T; Fencl, P; Jarkovsky, J; Simonova, K | 1 |
| Chmielowska, E; Chłosta, P; Drewa, T; Jasiński, M; Jóźwicki, W; Kamecki, K; Kraśnicki, K; Małkowski, B; Mikołajczak, W; Petrus, A; Pietrzak, T; Siekiera, J; Wronczewski, A | 1 |
| Catalano, PJ; Halasz, LM; Jacene, HA; Lacasce, A; Mauch, PM; Ng, AK; Van den Abbeele, AD | 1 |
| Abgral, R; Barberot, C; Chinellato, S; Garetier, M; Le Bivic, T; Potard, G; Rousset, J; Salaun, PY; Valette, G | 1 |
| Henne-Bruns, D; Hillenbrand, A; Luster, M; Ohlhauser, D; Reske, SN; Weber, T | 1 |
| Caldito, GC; Ekshyyan, O; Nathan, CA; Sibley, D; Sunderland, J; Vascoe, C | 1 |
| Casanova, N; Imperiano, H; Miralbell, R; Popowski, Y; Ratib, O; Vees, H; Wang, H; Zaidi, H; Zilli, T | 1 |
| Augeul-Meunier, K; Bodet-Milin, C; Dupas, B; Frampas, E; Gastinne, T; Le Gouill, S | 1 |
| Mikosch, P | 1 |
| Albertini, P; Alinari, L; Baccarani, M; Chierichetti, F; Ferlin, G; Garraffa, G; Stefoni, V; Tani, M; Tura, S; Zinzani, PL; Zompatori, M | 1 |
| Bredella, MA; Caputo, GR; Steinbach, LS | 1 |
| Beguin, Y; Belhocine, T; Fassotte, MF; Fillet, G; Hustinx, R; Jerusalem, G; Rigo, P | 1 |
| Alavi, A; Anderson, GS; Brinkmann, F; Soulen, MC; Zhuang, H | 1 |
| Beguin, Y; Fassotte, MF; Fillet, G; Foidart-Willems, J; Hustinx, R; Jérusalem, G; Silvestre, RM; Warland, V | 1 |
| Huang, KM; Hung, RL; Kao, CH; Lui, LT; Pan, MH; Wang, YH; Yen, RF | 1 |
| Bénard, F; Guay, C; Lépine, M; Verreault, J | 1 |
| Byrne, DW; Delbeke, D; Greer, JP; Hallahan, DE; Lavely, WC; Morgan, DS; Price, RR | 1 |
| Dannenberg, C; Dörffel, W; Hasenclever, D; Hirsch, W; Kluge, R; Körholz, D; Lotz, I; Lüders, H; Sabri, O; Wickmann, L | 1 |
| Hata, M; Inoue, T; Kinbara, K; Koike, I; Lee, J; Ogino, I; Ohmura, M; Oka, T; Ozawa, Y; Takahashi, N; Umezawa, T; Watai, K | 1 |
| Kitagawa, Y; Nakamura, M; Nishizawa, S; Ogasawara, T; Sano, K; Yonekura, Y | 1 |
| Bares, R; Bokemeyer, C; Claussen, CD; Dohmen, BM; Hartmann, JT; Kollmannsberger, C; Oechsle, K; Pfannenberg, AC; Vonthein, R | 1 |
| Becherer, A; Bokemeyer, C; De Santis, M; Dittrich, C; Dohmen, BM; Kletter, K; Lang, A; Oechsle, K; Pont, J; Sellner, F; Stoiber, F | 1 |
| De Santis, M; Pont, J | 1 |
| Bendandi, M; Boán, JF; García-Velloso, MJ; Panizo, C; Pérez-Salazar, M; Richter, J; Rocha, E; Rodríguez-Calvillo, M | 1 |
| Burrell, SC; Case, MA; Haddad, RI; McCollum, AD; Norris, CM; Posner, MR; Tishler, RB; Van den Abbeele, AD | 1 |
| Corry, J; Hicks, RJ; Hogg, A; Matthews, JP; Peters, LJ; Porceddu, S; Rischin, D; Ware, RE | 1 |
| Chen, LH; Chen, YR; Li, WX; Lin, YR | 1 |
| Devenyi, K; Illes, A; Keresztes, K; Lengyel, Z; Miltenyi, Z; Vadasz, G | 1 |
| Dai, JZ; Dong, MJ; Guan, YH; Lin, XT; Yu, DF; Zhao, J; Zuo, CT | 1 |
| Ballok, Z; Bolton, DM; Davis, ID; Hannah, A; Hicks, RJ; Johns Putra, L; Lawrentschuk, N; Poon, A; Putra, LJ; Scott, AM; Tauro, A | 1 |
| Corry, J; Hicks, RJ; Jarmolowski, E; Peters, LJ; Porceddu, SV; Rischin, D; Ware, R; Weih, L | 1 |
| Fukui, MB; Kapoor, V; McCook, BM | 1 |
| Ahn, SD; Choi, EK; Choi, SH; Im, KC; Kim, JH; Kim, JS; Kim, SB; Kim, SY; Lee, BJ; Lee, SW; Moon, DH; Nam, SY; Oh, SJ; Ryu, JS; Shin, SS; Yi, BY | 1 |
| Fee, WE; Le, QT; Pinto, HA; Ryan, WR | 1 |
| Becherer, A; Bokemeyer, C; De Santis, M; Dittrich, C; Dohmen, BM; Dudczak, R; Karanikas, G; Kletter, K; Pont, J; Szabó, M | 1 |
| Antoch, G; Bockisch, A; Forsting, M; Kuehl, H; Stergar, H; Veit, P | 1 |
| De Giorgi, U; Fiorentini, G; Marangolo, M; Pupi, A; Rosti, G | 1 |
| Buatti, JM; Chang, K; Dornfeld, KJ; Funk, GF; Graham, MM; Graham, SM; Hoffman, HT; Menda, Y; Smith, RB; Tan, H; Yao, M | 1 |
| Alterini, R; Bernardi, F; Bosi, A; Carpaneto, A; Carrai, V; Castagnoli, A; Dini, C; Matteini, M; Nassi, L; Pieroni, C; Rigacci, L | 1 |
| Ferlito, A; Genden, EM; Gourin, CG; Kowalski, LP; Leemans, CR; Lefebvre, JL; Lowry, J; Medina, JE; Pellitteri, PK; Rinaldo, A; Robbins, KT; Shah, JP; Shaha, AR; Suárez, C; Weber, RS; Wei, WI | 1 |
| Bibb, J; Hromas, R; Rabinowitz, I | 1 |
| Ciernik, IF; Eyrich, GK; Goerres, GW; Schuknecht, B; Stoeckli, SJ; Wild, D | 1 |
| Gong, HY; Yu, JM | 1 |
| Hoekstra, OS; Hooft, L; Huijgens, PC; Lindauer-van der Werf, G; Riphagen, II; Zijlstra, JM | 1 |
| Chen, AY; Halkar, R; Hudgins, PA; Schuster, D; Vilaseca, I | 1 |
| Guermazi, A; Juweid, ME | 1 |
| Andrade, RS; Avril, N; Branstetter, BF; Degirmenci, B; Ferris, RL; Filho, PA; Heron, DE; Seethala, RR | 1 |
| Chan, SC; Chang, JT; Chen, IH; Cheng, AJ; Fan, KH; Huang, SF; Kang, CJ; Liao, CT; Lin, CY; Lin, WJ; Ng, SH; Wang, HM; Yen, TC | 1 |
| Sakata, K; Shimizu, N; Yamamoto, I | 1 |
| Wooldridge, JE | 1 |
| Baudard, M; Comte, F; Conge, AM; Klein, B; Mariano-Goulart, D; Rossi, JF | 1 |
| Hayashi, T; Higashiyama, S; Kawabe, J; Kawamura, E; Kotani, J; Kurooka, H; Kusuki, M; Oe, A; Shiomi, S; Torii, K; Tsumoto, C; Tsushima, H; Yamane, H | 1 |
| Ajani, JA; Bresalier, R; Bruzzi, JF; Correa, AM; Erasmus, JJ; Fukami, N; Ho, JJ; Hofstetter, WL; Komaki, R; Lee, JH; Liao, Z; Macapinlac, HA; Marom, EM; Munden, RF; Sabloff, BS; Swisher, SG; Truong, MT; Wu, TT | 1 |
| Albrecht, S; Buchegger, F; Hany, TF; Husarik, D; Khan, H; Miralbell, R; Soloviev, D; Vees, H; Zaidi, H | 1 |
| Huang, XM; Li, WH; Zeng, L | 1 |
| Chao, KS | 1 |
| Hicks, RJ; Hogg, A; Januszewicz, H; Lee, M; Macmanus, M; Ng, AP; Prince, HM; Seymour, JF; Wirth, A; Wolf, M | 1 |
| Egerer, G; Eisenhut, M; Gronkowski, M; Haberkorn, U; Haufe, S; Ho, AD; Kasper, B; Lehnert, T; Mechtersheimer, G | 1 |
| Buccheri, V; Cerci, JJ; Chaves, AA; Meneghetti, JC; Pracchia, LF; Soares Junior, J | 1 |
| Adelstein, DJ; Carroll, MA; Esclamado, RM; Lorenz, RR; Rybicki, LA; Saxton, JP; Strome, M; Tan, A; Wood, BG | 1 |
| Specht, L | 1 |
| Chen, FJ; Chen, WK; Fan, W; Song, M; Wei, MW | 1 |
| Horiuchi, C; Inoue, T; Kawakami, M; Matsuda, H; Mikami, Y; Nishimura, G; Oka, T; Taguchi, T; Tanigaki, Y; Tsukuda, M; Yoshida, T | 1 |
| Brown, PD; Foote, RL; Garces, YI; Kasperbauer, JL; Lowe, VJ; Shintani, SA | 1 |
| Amthauer, H; Denecke, T; Hänninen, EL; Hildebrandt, B; Langrehr, J; Lehmkuhl, L; Ricke, J; Rühl, R; Steffen, I; Streitparth, F | 1 |
| Antoch, G; Barkhausen, J; Blechschmid, N; Bockisch, A; Diersch, O; Freudenberg, LS; Kuehl, H; Veit, P; Vogt, FM | 1 |
| Bai, YR; Huang, G; Liu, T; Xu, W; Yan, WL; Ye, M | 1 |
| He, ZY; Qiao, WL; Wang, C; Wang, TS; Xing, Y; Zhao, JH | 1 |
| Bouchelouche, K; Oehr, P | 1 |
| Jeong, HJ; Kim, DW; Lim, ST; Sohn, MH; Yim, CY | 1 |
| André, N; Colavolpe, C; Coze, C; Fabre, A; Gaudart, J; Gentet, JC; Guedj, E; Jacob, T; Michel, G; Mundler, O; Paris, M | 1 |
| Austin, JR; Kim, EE; Wong, FC | 1 |
| Dimitrakopoulou-Strauss, A; Goldschmidt, H; Lorenz, WJ; Maier-Borst, W; Strauss, LG; van Kaick, G | 1 |
| Bassa, P; Endo, K; Inoue, T; Kim, EE; Komaki, R; Podoloff, DA; Wong, FC; Wong, WH; Yang, DJ | 1 |
| Anscher, MS; Hebert, ME; Hoffman, JM; Lowe, VJ; Patz, EF | 1 |
| Bassa, P; Buzdar, AU; Hicks, KW; Inoue, T; Kim, EE; Korkmaz, M; Podoloff, DA; Wong, FC; Wong, WH; Yang, DJ | 1 |
| Bassa, P; Hicks, K; Inoue, T; Kim, EE; Korkmaz, M; Podoloff, DA; Tansey, W; Wong, FC; Wong, WH; Yang, DJ | 1 |
| Garcia, R; Kim, EE; Korkmaz, M; Podoloff, DA; Wong, FC; Wong, WH; Yang, DJ | 1 |
| Iwata, R; Kubota, K; Reinhardt, MJ; Yaegashi, H; Yamada, S | 1 |
| Dimitrakopoulou-Strauss, A; Goldschmidt, H; Hegenbart, U; Irngartinger, G; Oberdorfer, F; Strauss, LG; van Kaick, G | 1 |
| Beyer, W; Bumann, D; Clausen, M; de Wit, M; Herbst, K; Hossfeld, DK | 1 |
| Baddeley, H; Beaney, R; Chevretton, EB; Davis, J; Hussain, K; Maisey, M; McGurk, M; Tierney, P; Wong, WL | 1 |
| Elomaa, I; Joensuu, H; Leskinen, S; Minn, H; Nuutinen, JM; Salminen, E; Söderström, KO; Solin, O; Varpula, M | 1 |
| Eary, JF; Gold, P; Guinee, DG; Mankoff, DA; Samlowski, WE; Thompson, JA | 1 |
| Calvo, R; López Cabrerizo, MP; Martín, C; Martínez Roca, M; Maurel, J; Rosell, R | 1 |
| Adam, G; Buell, U; Cremerius, U; Effert, PJ; Jakse, G; Sabri, O; Wagenknecht, G; Zimmy, M | 1 |
| Rodriguez, M | 1 |
| AAssar, OS; Caputo, GR; Dillon, WP; Fischbein, NJ; Hawkins, RA; Kaplan, MJ; Price, DC; Singer, MI | 1 |
| Buell, U; Cremerius, U; Fabry, U; Neuerburg, J; Osieka, R; Zimny, M | 1 |
| Drane, WE; Jimenez, LA; Maria, BL; Mastin, ST | 1 |
| Saunders, M; Wong, WL | 1 |
| Hoh, CK; Schiepers, C | 1 |
| Clarke, MF; Francis, IR; Grossman, HB; Sugawara, Y; Wahl, RL; Zasadny, KR | 1 |
| Maxon, HR | 1 |
| Hanasono, MM; Ku, GH; Kunda, LD; Segall, GM; Terris, DJ | 1 |
| Alavi, A; Benard, F; Chalian, AA; Farber, LA; Machtay, M; Rosenthal, DI; Smith, RJ; Weber, RS; Weinstein, GS | 1 |
| Beguin, Y; Fassotte, MF; Fillet, G; Jerusalem, G; Najjar, F; Paulus, P; Rigo, P | 1 |
| Koh, JH; Pai, M; Park, CH; Suh, JH | 1 |
| Azuma, H; Ishii, Y; Kitagawa, Y; Ogasawara, T; Sadato, N; Yonekura, Y; Yoshida, M | 1 |
| Barthelemy, N; Bartsch, P; Bury, T; Corhay, JL; Daenen, F; Duysinx, B; Ghaye, B; Rigo, P | 1 |
| Hain, SF; Mikhaeel, NG; O'Doherty, MJ; Timothy, AR | 1 |
| Meyer, MA; Nathan, CO | 1 |
| Allal, A; Bang, P; Becker, M; Dulguerov, P; Guyot, JP; Haenggeli, CA; Lehmann, W; Slosman, D | 1 |
| Cunningham, DC; Flux, GD; Maisey, NR; Norman, A; Ott, RJ; Padhani, A; Webb, A | 1 |
| Barrington, SF; Bullock, P; Cox, T; Maisey, M; Pritchard, D; Robinson, RO; Wilmshurst, JM | 1 |
| Hain, SF; Harper, PG; Huddart, RA; Leslie, MD; O'Doherty, MJ; Timothy, AR | 1 |
| Fridrik, M; Hatzl-Griesenhofer, M; Huber, H; Maschek, W; Pichler, R; Wahl, G; Wimmer, G | 1 |
| Drucker, WD; Ghossein, RA; Larson, SM; Robbins, HK; Robbins, RJ; Sharaf, RN; Smith, A; Tuttle, RM | 1 |
| Balzarini, J; Bormans, G; De Wolf-Peeters, C; Dupont, P; Mortelmans, L; Spaepen, K; Stroobants, S; Thomas, J; Van Steenweghen, S; Vandenberghe, P; Vanuytsel, L; Verhoef, G | 1 |
| Bihl, H; Hültenschmidt, B; Lang, O; Sautter-Bihl, ML | 1 |
| Kuwert, T | 1 |
| Ang, KK; Byers, RM; Garden, AS; Gillenwater, AM; Morrison, WH; Nguyen, LN; Podoloff, DA; Schechter, NR | 1 |
| Becherer, A; Bokemeyer, C; De Santis, M; Dittrich, C; Dohmen, BM; Kletter, K; Oechsle, K; Pont, J; Stoiber, F | 1 |
| Golder, W | 1 |
| Balzarini, J; De Wolf-Peeters, C; Dupont, P; Mortelmans, L; Spaepen, K; Stroobants, S; Thomas, J; Vandenberghe, P; Verhoef, G | 1 |
| Buchmann, I; Reske, SN | 1 |
| Agoston, P; Bajzik, G; Dabasi, G; Esik, O; Repa, I; Sinkovics, I; Szakáll, S; Trón, L | 1 |
| Akhurst, T; Bains, M; Downey, RJ; Ginsberg, MS; Ginsberg, RJ; Gonen, M; Korst, R; Larson, SM; Rusch, VW | 1 |
| Ricart, Y | 1 |
| Kao, CH; Shen, YY; Shiau, YC; Yen, RF | 1 |
| Bares, R; Bokemeyer, C; Claussen, CD; Dohmen, BM; Kanz, L; Kollmannsberger, C; Oechsle, K; Pfannenberg, A | 1 |
37 review(s) available for fluorodeoxyglucose f18 and Minimal Disease, Residual
| Article | Year |
|---|---|
Progress of modern imaging modalities in multiple myeloma.
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Multiple Myeloma; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Tomography, X-Ray Computed | 2022 |
[Management of residual masses of testis germ cell tumors].
Topics: Biomarkers, Tumor; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Male; Neoplasm, Residual; Neoplasms, Germ Cell and Embryonal; Radiopharmaceuticals; Seminoma; Testicular Neoplasms | 2020 |
Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.
Topics: Fluorodeoxyglucose F18; Humans; Multiple Myeloma; Neoplasm Staging; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radioactive Tracers; Radiopharmaceuticals; Treatment Outcome | 2019 |
Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders.
Topics: ADP-ribosyl Cyclase 1; B-Cell Maturation Antigen; Biomarkers, Tumor; Bone Marrow; Disease Progression; Fluorodeoxyglucose F18; Gene Expression; Humans; Membrane Glycoproteins; Neoplasm Proteins; Neoplasm, Residual; Plasma Cells; Plasmacytoma; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptors, CXCR4; Smoldering Multiple Myeloma | 2020 |
Diagnostic Evaluation of 18F-FDG PET/CT Imaging in Recurrent or Residual Urinary Bladder Cancer: A Meta-Analysis.
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Urinary Bladder Neoplasms | 2020 |
Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Diffusion Magnetic Resonance Imaging; Drug Monitoring; Fluorodeoxyglucose F18; Humans; Ligands; Molecular Probes; Multiple Myeloma; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Receptors, CXCR4; Remission Induction; Tomography, X-Ray Computed | 2020 |
Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT.
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Multiple Myeloma; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Whole Body Imaging | 2022 |
Role of FDG PET-CT in the treatment management of Hodgkin lymphoma.
Topics: Antineoplastic Agents; Clinical Decision-Making; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymph Nodes; Lymphatic Irradiation; Neoplasm Staging; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy, Image-Guided | 2018 |
Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
Topics: Diffusion Magnetic Resonance Imaging; Fallopian Tube Neoplasms; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Neoplasm, Residual; Ovarian Neoplasms; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Tomography, X-Ray Computed | 2018 |
Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Endosonography; Esophageal Neoplasms; Esophagoscopy; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2020 |
Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor.
Topics: Carcinoma, Hepatocellular; Cholangiocarcinoma; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Multimodal Imaging; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
Allogeneic transplantation in the UK: an aggregation of marginal gains?
Topics: Chimerism; Fluorodeoxyglucose F18; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Infections; Neoplasm, Residual; Tissue Donors; Tomography, Emission-Computed; Transplantation, Homologous; Treatment Outcome; United Kingdom | 2013 |
Detection of residual tumor following radiofrequency ablation of liver metastases using 18F-FDG PET/PET-CT: a systematic review and meta-analysis.
Topics: Ablation Techniques; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Multimodal Imaging; Neoplasm Metastasis; Neoplasm, Residual; Positron-Emission Tomography; Radiofrequency Therapy; Tomography, X-Ray Computed | 2014 |
[Why is PET/CT essential in urooncology?].
Topics: Bone Neoplasms; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Multimodal Imaging; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Testicular Neoplasms; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2013 |
Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature.
Topics: Adult; Chemoradiotherapy; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Male; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Seminoma; Testicular Neoplasms; Tomography, X-Ray Computed | 2014 |
18F-FDG PET/CT for the Diagnosis of Residual or Recurrent Nasopharyngeal Carcinoma After Radiotherapy: A Metaanalysis.
Topics: Adolescent; Adult; Aged; Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Young Adult | 2016 |
Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical Trials as Topic; Cohort Studies; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Recurrence; Salvage Therapy; Sensitivity and Specificity; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2016 |
What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?
Topics: Fluorodeoxyglucose F18; Humans; Lymphoma, Mantle-Cell; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography | 2008 |
Established, emerging and future roles of PET/CT in the management of colorectal cancer.
Topics: Colonoscopy; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Sensitivity and Specificity; Tomography, X-Ray Computed; United Kingdom | 2009 |
[Imaging in oncology and international rules for evaluation: the nuclear medicine].
Topics: Fluorodeoxyglucose F18; Humans; Lymphoma; Neoplasm, Residual; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Radiopharmaceuticals | 2009 |
Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm.
Topics: Biomarkers, Tumor; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease.
Topics: Biopsy, Fine-Needle; Carcinoma, Squamous Cell; Chemoradiotherapy; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Neck Dissection; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
[End of treatment evaluation in patients with aggressive non-Hodgkin's lymphoma].
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lymphoma, Non-Hodgkin; Neoplasm, Residual; Radiography; Radiopharmaceuticals; Tomography, Emission-Computed; Treatment Outcome | 2002 |
The role of positron emission tomography in germ cell cancer.
Topics: Antineoplastic Agents; Cisplatin; Fluorodeoxyglucose F18; Germinoma; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Radiopharmaceuticals; Tomography, Emission-Computed | 2004 |
Role of 18FFDG PET/CT in the treatment of head and neck cancers: posttherapy evaluation and pitfalls.
Topics: Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Radiography, Interventional; Radiopharmaceuticals; Tomography, X-Ray Computed | 2005 |
FDG-PET in the management of germ cell tumor.
Topics: Adult; Fluorodeoxyglucose F18; Humans; Male; Mediastinal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Germ Cell and Embryonal; Positron-Emission Tomography; Predictive Value of Tests; Retroperitoneal Neoplasms; Testicular Neoplasms; Treatment Outcome | 2005 |
Planned neck dissection following chemoradiotherapy for advanced head and neck cancer: is it necessary for all?
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Neck Dissection; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed | 2006 |
[Current status of 18F-FDG PET in predicting outcome of cancer therapy].
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Treatment Outcome | 2004 |
18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review.
Topics: Fluorodeoxyglucose F18; Humans; Lymphoma; Neoplasm, Residual; Positron-Emission Tomography; Sensitivity and Specificity | 2006 |
2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Topics: Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Patient Care Planning; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Conformal; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review.
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Sensitivity and Specificity; Tomography, X-Ray Computed | 2007 |
Recent developments in urologic oncology: positron emission tomography molecular imaging.
Topics: Carbon Radioisotopes; Female; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Male; Neoplasm, Residual; Positron-Emission Tomography; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Testicular Neoplasms; Urinary Bladder Neoplasms | 2008 |
Role of PET FDG in the management of head and neck squamous cell cancer.
Topics: Carcinoma, Squamous Cell; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Patient Care Planning; Radiopharmaceuticals; Tomography, Emission-Computed | 1998 |
18-FDG imaging in breast cancer.
Topics: Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Staging; Neoplasm, Residual; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1999 |
Detection of residual and recurrent thyroid cancer by radionuclide imaging.
Topics: Fluorodeoxyglucose F18; Humans; Iodine Radioisotopes; Neoplasm Metastasis; Neoplasm, Residual; Radiopharmaceuticals; Recombinant Proteins; Recurrence; Technetium Tc 99m Sestamibi; Thallium Radioisotopes; Thyroid Neoplasms; Thyrotropin; Tomography, Emission-Computed, Single-Photon | 1999 |
Can positron emission tomography improve the quality of care for head-and-neck cancer patients?
Topics: Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Neoplasm, Residual; Neoplasms, Unknown Primary; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
Novel imaging techniques in NHL: clinical results with PET imaging.
Topics: Fluorodeoxyglucose F18; Humans; Lymphoma, Non-Hodgkin; Neoplasm Staging; Neoplasm, Residual; Prognosis; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
24 trial(s) available for fluorodeoxyglucose f18 and Minimal Disease, Residual
| Article | Year |
|---|---|
Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
Topics: Algorithms; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Organ Sparing Treatments; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2014 |
Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Fluorodeoxyglucose F18; Germany; Hodgkin Disease; Humans; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prednisone; Procarbazine; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Recurrence; Vincristine | 2015 |
Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gene Expression; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Real-Time Polymerase Chain Reaction; Recurrence | 2016 |
Diagnostic performance of 18F-FDG PET/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy.
Topics: Adolescent; Adult; Aged; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Positron Emission Tomography Computed Tomography; Recurrence; Whole Body Imaging; Young Adult | 2016 |
Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Postoperative Period; Predictive Value of Tests; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Risk Factors; Survival Rate; Treatment Outcome | 2008 |
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Predictive Value of Tests; Prednisone; Procarbazine; Radiography; Radiopharmaceuticals; Risk Factors; Survival Rate; Vincristine | 2008 |
Positron emission tomography in mantle cell lymphoma.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Non-Hodgkin; Male; Metabolism; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Remission Induction; Survival Analysis; T-Lymphocytes; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2009 |
Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Humans; Magnetic Resonance Imaging; Mammography; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Ultrasonography, Mammary | 2010 |
Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study.
Topics: Aged; Aged, 80 and over; Bone Marrow Cells; Carcinoma, Squamous Cell; Cell Proliferation; Diagnosis, Differential; Dideoxynucleosides; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm, Residual; Pilot Projects; Positron-Emission Tomography; Tomography, X-Ray Computed | 2010 |
Impact of a second FDG PET scan before adjuvant therapy for the early detection of residual/relapsing tumours in high-risk patients with oral cavity cancer and pathological extracapsular spread.
Topics: Adult; Aged; Chemoradiotherapy; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Mouth Neoplasms; Neoplasm, Residual; Positron-Emission Tomography; Radiotherapy, Adjuvant; Recurrence; Risk; Survival Analysis | 2012 |
Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses.
Topics: False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Male; Neoplasm, Residual; Positron-Emission Tomography; Recurrence; Survival Rate; Treatment Outcome | 2004 |
FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
Topics: Abdomen; Adult; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiographic Image Enhancement; Radiography, Abdominal; Radiography, Thoracic; Radiopharmaceuticals; Seminoma; Sensitivity and Specificity; Testicular Neoplasms; Thorax; Tomography, Spiral Computed | 2005 |
Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results.
Topics: Aged; Catheter Ablation; Colorectal Neoplasms; Contrast Media; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Iohexol; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Observer Variation; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2006 |
18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results.
Topics: Adolescent; Adult; Aged; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2005 |
Importance of [18F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Dendritic Cells; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Immunotherapy; Lymphoma, Follicular; Male; Middle Aged; Neoplasm, Residual; Prognosis; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Survival Rate; Tissue Distribution; Tomography, X-Ray Computed | 2007 |
Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma.
Topics: Adult; Aged; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Tomography, Emission-Computed; Whole-Body Counting | 1997 |
Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET.
Topics: Adult; Deoxyglucose; Diagnostic Errors; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Inflammation; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Germ Cell and Embryonal; Testicular Neoplasms; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1997 |
Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1999 |
FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study.
Topics: Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Glucose; Humans; Male; Middle Aged; Neoplasm, Residual; Pancreatic Neoplasms; Pilot Projects; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Survival Analysis; Tissue Distribution; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 2000 |
Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
Topics: Adolescent; Adult; alpha-Fetoproteins; Biomarkers, Tumor; Chorionic Gonadotropin, beta Subunit, Human; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Germinoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Radiopharmaceuticals; Retrospective Studies; Seminoma; Sensitivity and Specificity; Teratoma; Testicular Neoplasms; Tomography, Emission-Computed | 2000 |
Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
Topics: Adult; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm, Residual; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Seminoma; Sensitivity and Specificity; Testicular Neoplasms; Tomography, Emission-Computed | 2001 |
Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography: comparison with 18-fluoro-2-deoxyglucose positron emission
Topics: Adolescent; Adult; Aged; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm, Residual; Radiopharmaceuticals; Reproducibility of Results; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2002 |
183 other study(ies) available for fluorodeoxyglucose f18 and Minimal Disease, Residual
| Article | Year |
|---|---|
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.
Topics: Fluorodeoxyglucose F18; Humans; Multiple Myeloma; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2021 |
Molecular Signature of
Topics: Biomarkers; Fluorodeoxyglucose F18; Gene Expression Profiling; Humans; Multiple Myeloma; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2022 |
Prognostic value of pre-transplantation total metabolic tumor volume on
Topics: Fluorodeoxyglucose F18; Glucose; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Tumor Burden | 2022 |
Imaging minimal residual disease evaluation in multiple myeloma using [
Topics: Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Multiple Myeloma; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Role of peripheral blood MRD and 18F-FDG PET in the post-CAR relapse setting: a case study of discordant peripheral blood and bone marrow MRD.
Topics: Bone Marrow; Burkitt Lymphoma; Child; Female; Fluorodeoxyglucose F18; Humans; Leukemia; Neoplasm, Residual; Positron-Emission Tomography; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2023 |
PET-CT detection of local residual laryngeal carcinoma after definitive (chemo)radiotherapy.
Topics: Carcinoma; Chemoradiotherapy; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies | 2023 |
Refractory Burkitt Lymphoma With False-positive and False-negative Mass Detected on Positron Emission Tomography-computed Tomography After Chemotherapy.
Topics: Burkitt Lymphoma; Child, Preschool; Fluorodeoxyglucose F18; Humans; Male; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
The Role Of 18F-FDG PET/CT In Evaluation Of Primary CNS Lymphoma: The Path Less Travelled.
Topics: Aggression; Fluorodeoxyglucose F18; Humans; Immunocompromised Host; Neoplasm, Residual; Positron Emission Tomography Computed Tomography | 2023 |
Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial.
Topics: Adult; Bone Marrow; Fluorodeoxyglucose F18; Humans; Lymphoma, Mantle-Cell; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2023 |
Re: Delayed
Topics: Fluorodeoxyglucose F18; Humans; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Urinary Bladder Neoplasms | 2020 |
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Genetic Testing; Head and Neck Neoplasms; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2020 |
Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Fluorodeoxyglucose F18; Humans; Laparoscopy; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Ovarian Neoplasms; Ovary; Positron Emission Tomography Computed Tomography; Progression-Free Survival; Radiopharmaceuticals; Response Evaluation Criteria in Solid Tumors; Retrospective Studies | 2020 |
Can FDG-PET replace biopsy for the evaluation of residual tumor in pediatric mature B-cell non-Hodgkin lymphoma?
Topics: Adolescent; Biopsy; Child; Child, Preschool; Cross-Sectional Studies; Egypt; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, B-Cell; Male; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Retrospective Studies; Sensitivity and Specificity | 2020 |
Pre-treatment prediction of early response to chemoradiotherapy by quantitative analysis of baseline staging FDG-PET/CT and MRI in locally advanced cervical cancer.
Topics: Adult; Aged; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Treatment Outcome; Uterine Cervical Neoplasms | 2021 |
Standardization of
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Fluorodeoxyglucose F18; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stem Cell Transplantation | 2021 |
Detection of residual head and neck squamous cell carcinoma after (chemo)radiotherapy: a pilot study assessing the value of diffusion-weighted magnetic resonance imaging as an adjunct to PET-CT using
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Diffusion Magnetic Resonance Imaging; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm, Residual; Pilot Projects; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity | 2017 |
18F-FDG-PET/CT for the detection of disease in patients with head and neck cancer treated with radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Squamous Cell Carcinoma of Head and Neck | 2017 |
Detection of Non-FDG-Avid Residual Sinonasal Malignant Melanoma in the Skull Base With 11C-Choline PET and Contrast-Enhanced MRI.
Topics: Carbon Radioisotopes; Choline; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Melanoma; Middle Aged; Multimodal Imaging; Neoplasm, Residual; Positron-Emission Tomography; Skull Base | 2017 |
Fluorine-18-fluorodeoxyglucose uptake of bone marrow on PET/CT can predict prognosis in patients with colorectal cancer after curative surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; C-Reactive Protein; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lymphatic Vessels; Lymphocyte Count; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Neutrophils; Platelet Count; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Survival Rate; Tumor Burden | 2018 |
Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study.
Topics: Adult; Aged; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Middle Aged; Molecular Imaging; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Treatment Outcome; Whole Body Imaging | 2018 |
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Prognosis; Survival Analysis; Treatment Outcome | 2018 |
Clinical significance of the post-radiotherapy
Topics: Adolescent; Adult; Aged; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymph Nodes; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Time Factors; Young Adult | 2019 |
Solitary Benign Schwannoma Mimics Residual Malignancy on FDG PET/CT.
Topics: Adolescent; Biopsy; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Neoplasm, Residual; Neurilemmoma; Positron Emission Tomography Computed Tomography | 2018 |
Diagnostic Accuracy of 18F-FDG PET/CT in Patients With Biochemical Evidence of Recurrent, Residual, or Metastatic Medullary Thyroid Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Recurrence; Retrospective Studies; Sensitivity and Specificity; Thyroid Neoplasms; Young Adult | 2019 |
FDG-PET/CT improves detection of residual disease and reduces the need for examination under anaesthesia in oropharyngeal cancer patients treated with (chemo-)radiation.
Topics: Adult; Aged; Aged, 80 and over; Anesthesia; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm, Residual; Oropharyngeal Neoplasms; Positron Emission Tomography Computed Tomography; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2019 |
Postchemotherapy Histiocyte-Rich Pseudotumor of the Spleen Simulating Residual Disease in a Patient With Non-Hodgkin Lymphoma on FDG PET/CT.
Topics: Antineoplastic Agents; Diagnosis, Differential; Fluorodeoxyglucose F18; Granuloma, Plasma Cell; Histiocytes; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Spleen | 2019 |
Potential pitfall of FDG PET/CT in assessing residual masses postchemotherapy.
Topics: Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mediastinal Neoplasms; Multimodal Imaging; Neoplasm, Residual; Positron-Emission Tomography; Tomography, X-Ray Computed; Young Adult | 2013 |
The German evidence-based guidelines for Hodgkin's lymphoma. Aspects for radiation oncologists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cooperative Behavior; Evidence-Based Medicine; Fluorodeoxyglucose F18; Germany; Hodgkin Disease; Humans; Interdisciplinary Communication; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Radiotherapy Dosage | 2013 |
Which is the most reliable diagnostic modality for detecting locally residual or recurrent laryngeal squamous cell carcinoma after (chemo)radiotherapy?
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Laryngeal Neoplasms; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Tomography, X-Ray Computed | 2013 |
Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, B-Cell; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Rituximab; Young Adult | 2013 |
Is FDG -PET-CT a valuable tool in prediction of persistent disease in head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed; Young Adult | 2013 |
Proposal of a new 18F-FDG PET/CT predictor of response in rectal cancer treated by neoadjuvant chemoradiation therapy and comparison with PERCIST criteria.
Topics: Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Positron-Emission Tomography; Rectal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Voxel-based dual-time 18F-FDG parametric imaging for rectal cancer: differentiation of residual tumor from postchemoradiotherapy changes.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Positron-Emission Tomography; Rectal Neoplasms; Time Factors; Treatment Outcome | 2013 |
Radiotherapy response in head and neck cancer - evaluation of the primary tumour site.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Endoscopy; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm, Residual; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Intraluminal Superior Vena Cava Metastasis in a Patient With Poorly Differentiated Thyroid Carcinoma.
Topics: Adenocarcinoma; Aged; Cough; Deglutition Disorders; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Adjuvant; Recurrence; Respiratory Sounds; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed; Vascular Neoplasms; Vena Cava, Superior | 2015 |
Comparison of (68)Ga DOTATATE to 18F-FDG uptake is useful in the differentiation of residual or recurrent pituitary adenoma from the remaining pituitary tissue after transsphenoidal adenomectomy.
Topics: Adenoma; Adult; Cicatrix; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Organometallic Compounds; Pituitary Gland; Pituitary Neoplasms; Radionuclide Imaging; Sphenoid Bone | 2014 |
Predictive value of pattern classification 24 hours after radiofrequency ablation of liver metastases on CT and positron emission tomography/CT.
Topics: Catheter Ablation; Contrast Media; Disease Progression; Fluorodeoxyglucose F18; Humans; Iohexol; Liver Neoplasms; Metastasectomy; Multimodal Imaging; Neoplasm, Residual; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Cardiac angiosarcoma: utility of [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography in evaluation of residue, metastases, and treatment response.
Topics: Biopsy; Cardiac Surgical Procedures; Fatal Outcome; Fluorodeoxyglucose F18; Heart Neoplasms; Hemangiosarcoma; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm, Residual; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy, Adjuvant; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Whole Body Imaging | 2014 |
Value of 18F-FDG PET/CT for early prediction of pathologic response (by residual cancer burden criteria) of locally advanced breast cancer to neoadjuvant chemotherapy.
Topics: Adult; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Planned neck dissection after chemoradiotherapy in advanced oropharyngeal squamous cell cancer: the role of US, MRI and FDG-PET/TC scans to assess residual neck disease.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Diagnostic Imaging; Female; Fluorodeoxyglucose F18; Gadolinium DTPA; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neck Dissection; Neoplasm, Residual; Oropharyngeal Neoplasms; Patient Care Planning; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed; Ultrasonography, Doppler, Color | 2014 |
Validation of nonrigid registration in pretreatment and follow-up PET/CT scans for quantification of tumor residue in lung cancer patients.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm, Residual; Organometallic Compounds; Positron-Emission Tomography; Retrospective Studies; Technetium Tc 99m Dimercaptosuccinic Acid; Thyroid Neoplasms; Tomography, X-Ray Computed; Whole Body Imaging; Young Adult | 2015 |
The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma.
Topics: Adolescent; Biopsy; Child; Child, Preschool; Disease Progression; Fluorodeoxyglucose F18; Humans; Lymphoma, Non-Hodgkin; Multimodal Imaging; Neoplasm, Residual; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed; Young Adult | 2015 |
Three-dimensional texture analysis of contrast enhanced CT images for treatment response assessment in Hodgkin lymphoma: comparison with F-18-FDG PET.
Topics: Adolescent; Adult; Biophysical Phenomena; Child; Contrast Media; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Imaging, Three-Dimensional; Logistic Models; Lymph Nodes; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Tomography, X-Ray Computed; Young Adult | 2014 |
Glucose-corrected standardized uptake value in the differentiation of high-grade glioma versus post-treatment changes.
Topics: Adult; Aged; Biological Transport; Blood Glucose; Brain Neoplasms; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Positron-Emission Tomography; Recurrence | 2015 |
[Value of FDG PET-CT associated with pathology in diagnosing residual tumor in patients with nasopharyngeal carcinoma after radiotherapy].
Topics: Carcinoma; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Sensitivity and Specificity; Tomography, X-Ray Computed | 2015 |
Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography for Follow-Up of 13-cis-Retinoic Acid Treatment for Residual Neuroblastoma After Myeloablative Chemotherapy.
Topics: Abdominal Neoplasms; Child; Combined Modality Therapy; Dermatologic Agents; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Isotretinoin; Male; Neoplasm, Residual; Neuroblastoma; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2015 |
Accuracy of (18) FDG PET-CT for treatment evaluation 3 months after completion of chemoradiotherapy for head and neck squamous cell carcinoma: 2-year minimum follow-up.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2016 |
The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Monitoring; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Prevalence; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Republic of Korea; Retrospective Studies; Risk Factors; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2016 |
Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.
Topics: Adult; Clinical Decision-Making; Female; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphocyte Depletion; Male; Neoplasm, Residual; Positron-Emission Tomography; Recurrence; Retrospective Studies; Survival Analysis; T-Lymphocytes; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2016 |
Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2016 |
Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; False Negative Reactions; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Recurrence; Retrospective Studies | 2016 |
18F-NaF PET/CT Images of Cardiac Metastasis From Osteosarcoma.
Topics: Adolescent; Bone Neoplasms; Fluorodeoxyglucose F18; Heart Neoplasms; Humans; Male; Multimodal Imaging; Neoplasm, Residual; Osteosarcoma; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2016 |
[A Case of Metastatic Seminomatous Testicular Tumor with Complicated Diagnosis by FDG-PET].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Germ Cell and Embryonal; Orchiectomy; Positron-Emission Tomography; Radiopharmaceuticals; Seminoma; Testicular Neoplasms; Treatment Outcome | 2016 |
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Immunotherapy; Leucovorin; Liver; Lymphoma, B-Cell; Male; Mediastinal Neoplasms; Methotrexate; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Prednisone; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Conformal; Recurrence; Rituximab; Statistics, Nonparametric; Vincristine; Young Adult | 2017 |
Adenoid cystic carcinoma of the trachea treated with PET-CT based intensity modulated radiotherapy.
Topics: Carcinoma, Adenoid Cystic; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Radiography, Interventional; Radiopharmaceuticals; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed; Tracheal Neoplasms | 2008 |
Evaluation of the therapeutic effects and recurrence for head and neck cancer after chemoradiotherapy by FDG-PET.
Topics: Adolescent; Adult; Aged; Carcinoma; Child; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Otorhinolaryngologic Neoplasms; Positron-Emission Tomography; Sensitivity and Specificity; Tomography, X-Ray Computed; Young Adult | 2009 |
Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative.
Topics: 3-Iodobenzylguanidine; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Infant; Neoplasm Recurrence, Local; Neoplasm, Residual; Neuroblastoma; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT.
Topics: Adolescent; Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed | 2008 |
Central photopenic lesions on FDG-PET scan in a patient with peripheral T cell lymphoma.
Topics: Alcoholism; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Biomarkers, Tumor; Biopsy; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Tomography, X-Ray Computed; Whole Body Imaging | 2008 |
Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy.
Topics: Combined Modality Therapy; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Predictive Value of Tests; Proctitis; Prospective Studies; Radiation Injuries; Radiopharmaceuticals; Radiotherapy Dosage; Rectal Neoplasms; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2009 |
Combined use of perioperative TSH-stimulated (18)F-FDG PET/CT imaging and gamma probe radioguided surgery to localize and verify resection of iodine scan-negative recurrent thyroid carcinoma.
Topics: Carcinoma, Papillary; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Gamma Rays; Humans; Image Processing, Computer-Assisted; Iodine Radioisotopes; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Radiotherapy, Adjuvant; Sensitivity and Specificity; Surgery, Computer-Assisted; Thyroid Neoplasms; Thyrotropin; Tomography, X-Ray Computed; Young Adult | 2008 |
[18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group.
Topics: Adolescent; Adult; Biomarkers, Tumor; Cell Survival; Cisplatin; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Germ Cell and Embryonal; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Retroperitoneal Neoplasms; Sensitivity and Specificity; Testicular Neoplasms; Tomography, X-Ray Computed | 2008 |
I-131, I-123, and F-18 FDG-PET imaging in a patient with diffuse sclerosing variant of papillary thyroid cancer.
Topics: Carcinoma, Papillary; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Iodine Radioisotopes; Middle Aged; Neoplasm Metastasis; Neoplasm, Residual; Positron-Emission Tomography; Thyroid Neoplasms; Tomography, X-Ray Computed | 2008 |
Early experience with PET/CT scan in the evaluation of pediatric abdominal neoplasms.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Child; Drug Monitoring; Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Postoperative Care; Preoperative Care; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2008 |
Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Outcome Assessment, Health Care; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Fluorodeoxyglucose F18; Genetic Variation; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm, Residual; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Recombinant Proteins; Sensitivity and Specificity; Thyroid Neoplasms; Thyroidectomy; Thyrotropin; Tomography, X-Ray Computed | 2009 |
Advanced head and neck cancer: is there a role for fluorodeoxyglucose PET/computed tomography?
Topics: Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Neoplasm, Residual; Positron-Emission Tomography; Recurrence; Sensitivity and Specificity; Tomography, X-Ray Computed | 2009 |
Positron emission tomography-computed tomography surveillance for the node-positive neck after chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Enhancement; Image Processing, Computer-Assisted; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Otorhinolaryngologic Neoplasms; Positron-Emission Tomography; Radiotherapy, Conformal; Sensitivity and Specificity; Tomography, X-Ray Computed | 2009 |
Absence of residual Hodgkin's disease demonstrated by PET/CT in a deceased organ donor.
Topics: Adult; Brain Death; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Tissue and Organ Procurement; Tissue Donors; Tomography, X-Ray Computed | 2010 |
Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer.
Topics: Biopsy, Fine-Needle; Carcinoma, Squamous Cell; Disease Progression; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Multiple Primary; Neoplasms, Unknown Primary; Otorhinolaryngologic Neoplasms; Positron-Emission Tomography; Sensitivity and Specificity; Tomography, X-Ray Computed; Tumor Burden; Ultrasonography | 2010 |
Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Hormone-Dependent; Positron-Emission Tomography; Prognosis; Receptors, Estrogen; Treatment Outcome | 2010 |
Remnant pancreatectomy for recurrent or metachronous pancreatic carcinoma detected by FDG-PET: two case reports.
Topics: Aged; Carcinoma; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Second Primary; Pancreatectomy; Pancreatic Neoplasms; Radionuclide Imaging | 2010 |
Textiloma on 18F-fluorodeoxyglucose positron emission tomography/computed tomography: a wolf in a sheep's clothing?
Topics: Adult; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Foreign Bodies; Humans; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Thoracic Neoplasms; Tomography, X-Ray Computed | 2010 |
Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed; Whole Body Imaging; Young Adult | 2010 |
Exposing the evil in the dark: the usefulness of delayed-phase FDG PET scan to enhance the detectability of tiny residual skull base osteosarcoma initially concealed by adjacent high physiological brain activity.
Topics: Brain; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm, Residual; Osteosarcoma; Positron-Emission Tomography; Sensitivity and Specificity; Skull Base Neoplasms; Time Factors; Tomography, X-Ray Computed | 2010 |
Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Algorithms; Disease Progression; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Ovariectomy; Positron-Emission Tomography; Prognosis; Survival Analysis | 2011 |
Prediction of residual metabolic activity after treatment in NSCLC patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Retrospective Studies; Treatment Failure | 2010 |
αvβ3 imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study.
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Cisplatin; Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Integrin alphaVbeta3; Male; Molecular Imaging; Necrosis; Neoplasm, Residual; Rats; Teratoma; Testicular Neoplasms; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Tretinoin | 2011 |
[The role of PET imaging in patients with lymphoma].
Topics: Antineoplastic Agents; Disease Progression; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lymphoma; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2010 |
Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head-and-neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm, Residual; Physical Examination; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Failure; Young Adult | 2011 |
FDG PET imaging of head and neck cancers.
Topics: Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals | 2011 |
Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing salvage surgery for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Salvage Therapy; Tomography, X-Ray Computed | 2011 |
Neck dissection can be avoided after sequential chemoradiotherapy and negative post-treatment positron emission tomography-computed tomography in N2 head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Radiography; Radiopharmaceuticals; Survival Rate; Tomography, Emission-Computed | 2011 |
Residual metabolic tumor activity after chemo-radiotherapy is mainly located in initially high FDG uptake areas in rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Rectal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Multiple Myeloma; Neoplasm, Residual; Positron-Emission Tomography; Recurrence; Reference Standards; Reproducibility of Results; Retrospective Studies; Stem Cell Transplantation; Tomography, X-Ray Computed; Transplantation, Autologous; Transplantation, Homologous | 2012 |
Primary leiomyosarcoma of the pulmonary artery: a case of a 20-month survivor after incomplete surgical resection.
Topics: Diagnosis, Differential; Fatal Outcome; Fluorodeoxyglucose F18; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Pulmonary Artery; Pulmonary Embolism; Radiopharmaceuticals; Vascular Neoplasms | 2012 |
Successful treatment of duodenal myeloid sarcoma with allogeneic bone marrow transplantation and additional radiotherapy.
Topics: Adult; Bone Marrow Transplantation; Duodenal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Multimodal Imaging; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Remission Induction; Sarcoma, Myeloid; Tomography, X-Ray Computed; Transplantation, Homologous | 2012 |
Clinical outcomes of patients with nonseminomatous germ cell tumours and negative postchemotherapy positron emission tomography.
Topics: Adolescent; Adult; Disease-Free Survival; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Germ Cell and Embryonal; Positron-Emission Tomography; Predictive Value of Tests; Teratoma; Testicular Neoplasms; Young Adult | 2012 |
Can we rely on PET in the follow-up of advanced seminoma patients?
Topics: Antineoplastic Agents; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Multimodal Imaging; Neoplasm, Residual; Poland; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Seminoma; Testicular Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prednisone; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies; Rituximab; Treatment Failure; Vincristine; Young Adult | 2012 |
Early recurrence or submucosal residual of laryngeal squamous cell carcinoma: diagnosis by CT-guided endolaryngeal core biopsy on a transcutaneous approach.
Topics: Carcinoma, Squamous Cell; Fluorodeoxyglucose F18; Humans; Laryngeal Neoplasms; Larynx; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2013 |
Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
Topics: Adenocarcinoma, Follicular; Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma; Carcinoma, Papillary; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reoperation; Sensitivity and Specificity; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tomography, X-Ray Computed; Young Adult | 2012 |
18F-fluorodeoxythymidine micro-positron-emission tomography versus 18F-fluorodeoxyglucose micro-positron-emission tomography for in vivo minimal residual disease imaging.
Topics: Animals; Carcinoma, Squamous Cell; Dideoxynucleosides; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Luminescent Measurements; Mice; Mice, Nude; Neoplasm, Residual; Positron-Emission Tomography; Prospective Studies; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2013 |
Impact of 18F-FDG PET/CT on target volume delineation in recurrent or residual gynaecologic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Genital Neoplasms, Female; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm, Residual; Observer Variation; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2012 |
Staging and monitoring in the treatment of lymphomas.
Topics: Biopsy; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Image-Guided Biopsy; Interdisciplinary Communication; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Multimodal Imaging; Neoplasm Staging; Neoplasm, Residual; Radiography; Radionuclide Imaging; Treatment Outcome | 2013 |
[F-18 fluorodeoxyglucose positron emission tomography in malignant lymphoma].
Topics: Fluorodeoxyglucose F18; Humans; Lymphoma; Neoplasm Staging; Neoplasm, Residual; Sensitivity and Specificity; Tomography, Emission-Computed; Treatment Outcome | 2002 |
Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma; Male; Middle Aged; Neoplasm, Residual; Radiopharmaceuticals; Recurrence; Remission Induction; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 2002 |
Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Contrast Media; Female; Fluorodeoxyglucose F18; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Radiopharmaceuticals; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tomography, Emission-Computed | 2002 |
Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.
Topics: Adolescent; Adult; Aged; False Negative Reactions; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hodgkin Disease; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Prospective Studies; Radiopharmaceuticals; Thymus Gland; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Carcinoma, Transitional Cell; Catheter Ablation; Colonic Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Insulinoma; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Pancreatic Neoplasms; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sarcoma; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome; Whole-Body Counting | 2003 |
18-fluoro-2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging.
Topics: Adolescent; Adult; Aged; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm, Residual; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2003 |
Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Radiography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Treatment Outcome | 2003 |
FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy.
Topics: Adolescent; Adult; Aged; Child; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Tomography, Emission-Computed | 2003 |
Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence - consequences for the GPOH-HD 2003 protocol.
Topics: Adolescent; Blood Glucose; Child; Combined Modality Therapy; Disease-Free Survival; Fluorodeoxyglucose F18; Follow-Up Studies; Hodgkin Disease; Humans; Neoplasm Staging; Neoplasm, Residual; Prognosis; Radiotherapy, Adjuvant; Sensitivity and Specificity; Tomography, Emission-Computed; Treatment Outcome; Whole-Body Counting | 2003 |
FDG-PET scanning after radiation can predict tumor regrowth three months later.
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms; Predictive Value of Tests; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
Diagnostic significance of FDG-PET and argyrophilic nucleolar organizer regions (AgNORs) in oral squamous cell carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Neoplasm, Residual; Nucleolus Organizer Region; Prognosis; Radiopharmaceuticals; Silver Staining; Tomography, Emission-Computed | 2004 |
The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management.
Topics: Adult; Biomarkers, Tumor; Fluorodeoxyglucose F18; Germinoma; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2004 |
2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
Topics: Austria; Clinical Trials as Topic; Fluorodeoxyglucose F18; Follow-Up Studies; Germany; Humans; Male; Neoplasm, Residual; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Seminoma; Sensitivity and Specificity; Testicular Neoplasms; Tomography, Emission-Computed | 2004 |
[2003 update of recommendations for clinical practice: standards, options and recommendations for the use of FDG-PET in the management of gynaecological and breast cancers].
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Genital Neoplasms, Female; Humans; Neoplasm Metastasis; Neoplasm, Residual; Ovarian Neoplasms; Tomography, Emission-Computed; Uterine Neoplasms; Vaginal Neoplasms | 2004 |
Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymph Nodes; Male; Middle Aged; Neck; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Adjuvant; Sensitivity and Specificity; Treatment Outcome | 2004 |
Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck.
Topics: Aged; Carcinoma, Squamous Cell; Cohort Studies; Combined Modality Therapy; Confidence Intervals; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Prospective Studies; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Tomography, X-Ray Computed | 2004 |
[Value of 18F-FDG PET imaging in diagnosing tumor residue of intracranial glioma after surgery and radiotherapy].
Topics: Adult; Astrocytoma; Brain Neoplasms; Female; Fluorodeoxyglucose F18; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Mediastinal bulky tumour in Hodgkin's disease and prognostic value of positron emission tomography in the evaluation of post-treatment residual masses.
Topics: Child; Child, Preschool; Diagnostic Errors; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hodgkin Disease; Humans; Infant; Male; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Recurrence; Retrospective Studies; Survival Rate | 2004 |
[Application of 18F-FDG PET/CT scan in following-up of nasopharyngeal carcinoma after radiotherapy].
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2004 |
18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy.
Topics: Adult; Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Germinoma; Humans; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Salvage Therapy; Seminoma | 2004 |
Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy Dosage | 2005 |
Early evaluation of the response to radiotherapy of patients with squamous cell carcinoma of the head and neck using 18FDG-PET.
Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Treatment Outcome | 2005 |
Positron-emission tomography for surveillance of head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2005 |
The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed; Tongue Neoplasms | 2005 |
A Bayesian approach to a patient with a residual mass after treatment for non-Hodgkin's lymphoma of the thyroid.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neck; Neoplasm, Residual; Positron-Emission Tomography; Prednisone; Radiotherapy, Adjuvant; Remission Induction; Rituximab; Thyroid Neoplasms; Vincristine | 2005 |
In-line (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) in patients with carcinoma of the sinus/nasal area and orbit.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Second Primary; Nose Neoplasms; Orbital Neoplasms; Paranasal Sinus Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, Spiral Computed; Whole Body Imaging | 2006 |
PET-CT vs contrast-enhanced CT: what is the role for each after chemoradiation for advanced oropharyngeal cancer?
Topics: Adult; Aged; Carcinoma, Squamous Cell; Contrast Media; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Male; Middle Aged; Neck; Neoplasm, Residual; Oropharyngeal Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy, Adjuvant; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Commentary: PET poised to alter the current paradigm for response assessment of non-Hodgkin's lymphoma.
Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Practice Guidelines as Topic; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers.
Topics: Adult; Aged; Carcinoma, Squamous Cell; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2006 |
18F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Statistics, Nonparametric | 2006 |
Benign osteoblastoma of the temporal bone: Case report and review of the literature.
Topics: Aged; Bone Neoplasms; Embolization, Therapeutic; Female; Fluorodeoxyglucose F18; Hearing Loss; Humans; Intraoperative Complications; Neoplasm, Residual; Neuronavigation; Neurosurgical Procedures; Osteoblastoma; Positron-Emission Tomography; Postoperative Hemorrhage; Radiography; Temporal Bone; Tinnitus; Treatment Outcome | 2006 |
Can a positive positron emission tomography scan be positive news?
Topics: Cancer Vaccines; Combined Modality Therapy; Dendritic Cells; Fluorodeoxyglucose F18; Humans; Immunotherapy; Lymphoma, Follicular; Neoplasm, Residual; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity | 2007 |
Detection of local residual tumor after laryngeal cancer treatment using FDG-PET.
Topics: Aged; Female; Fluorodeoxyglucose F18; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Retrospective Studies | 2007 |
Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging.
Topics: Adult; Aged; Combined Modality Therapy; Esophageal Diseases; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed; Ulcer | 2006 |
18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.
Topics: Acetates; Aged; Carbon Radioisotopes; Choline; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiopharmaceuticals; Salvage Therapy; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
[Clinical value of 18FDG-PET in diagnosing and detecting residue or recurrence of nasopharyngeal carcinoma].
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography | 2007 |
3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Disease Models, Animal; Docetaxel; Esophageal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Forecasting; Humans; Mice; Neoadjuvant Therapy; Neoplasm, Residual; Positron-Emission Tomography; Radiotherapy, Adjuvant; Remission Induction; Taxoids; Treatment Outcome | 2007 |
Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Treatment Failure | 2007 |
Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dideoxynucleosides; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals | 2007 |
Metabolic test with fluorine-18-fluorodeoxyglucose in staging and detection of residual tumor or recurrence in Hodgkin lymphoma.
Topics: Adolescent; Adult; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed | 2007 |
Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Neck Dissection; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy Dosage; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity | 2007 |
[Roles of single photo emission computed tomography-CT in detecting residual tumor from patients with thyroid carcinoma].
Topics: Adolescent; Adult; Aged; Child; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm, Residual; Thyroid Neoplasms; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Young Adult | 2007 |
Early assessment of clinical response to concurrent chemoradiotherapy in head and neck carcinoma using fluoro-2-deoxy-d-glucose positron emission tomography.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Glucose; Carcinoma, Squamous Cell; Cell Survival; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Otorhinolaryngologic Neoplasms; Positron-Emission Tomography; Prognosis; Radiotherapy Dosage; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Biopsy; Carcinoma, Squamous Cell; Chi-Square Distribution; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Adjuvant; Time Factors; Tomography, X-Ray Computed | 2008 |
Assessment of local control after laser-induced thermotherapy of liver metastases from colorectal cancer: contribution of FDG-PET in patients with clinical suspicion of progressive disease.
Topics: Adult; Aged; Catheter Ablation; Colorectal Neoplasms; Diagnostic Errors; Disease Progression; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Hyperthermia, Induced; Laser Therapy; Liver Neoplasms; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; ROC Curve; Sensitivity and Specificity | 2007 |
Morphologic and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT.
Topics: Animals; Catheter Ablation; Fluorodeoxyglucose F18; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Necrosis; Neoplasm, Residual; Positron-Emission Tomography; Radiopharmaceuticals; Swine; Swine, Miniature; Tomography, X-Ray Computed; Ultrasonography | 2007 |
[Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Diagnosis, Differential; Disease Progression; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Radiopharmaceuticals; Remission Induction; Retrospective Studies; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2007 |
F-18 FDG PET-CT findings of intraperitoneal carbon particles-induced granulomas mimicking peritoneal carcinomatosis.
Topics: Adult; Carbon; Diagnosis, Differential; Extravasation of Diagnostic and Therapeutic Materials; False Positive Reactions; Female; Fluorodeoxyglucose F18; Granuloma, Foreign-Body; Humans; Male; Middle Aged; Mitomycin; Neoplasm, Residual; Particle Size; Peritoneal Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Stomach Neoplasms; Tomography, X-Ray Computed | 2008 |
FDG PET and evaluation of posttherapeutic residual tumors in pediatric oncology: preliminary experience.
Topics: Adolescent; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasm, Residual; Positron-Emission Tomography; Recurrence; Retrospective Studies; Treatment Outcome | 2008 |
Positron emission tomography in the detection of residual laryngeal carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxyglucose; Edema; Fibrosis; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Laryngeal Diseases; Laryngeal Neoplasms; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplasm, Residual; Predictive Value of Tests; Radiotherapy Dosage; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1995 |
Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxyglucose; Drug Resistance, Multiple; Fluorodeoxyglucose F18; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Neoplasm, Residual; Oxygen Radioisotopes; Sensitivity and Specificity; Technetium Tc 99m Sestamibi; Time Factors; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Water | 1995 |
Detecting recurrent or residual lung cancer with FDG-PET.
Topics: Adult; Aged; Aged, 80 and over; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Sensitivity and Specificity; Tomography, Emission-Computed | 1995 |
Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings.
Topics: Carcinoma in Situ; Carcinoma, Non-Small-Cell Lung; Cicatrix; Deoxyglucose; Fibrosis; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung; Lung Diseases; Lung Neoplasms; Neoplasm, Residual; Prospective Studies; Remission Induction; Survival Rate; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 1996 |
Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Mammography; Middle Aged; Neoplasm, Residual; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Ultrasonography, Mammary | 1996 |
Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Methionine; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Sensitivity and Specificity; Soft Tissue Neoplasms; Tomography, Emission-Computed | 1996 |
Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas.
Topics: Adult; Bone Neoplasms; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Muscle Neoplasms; Neoplasm Recurrence, Local; Neoplasm, Residual; Sarcoma; Sensitivity and Specificity; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1996 |
Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine.
Topics: Animals; Autoradiography; Carbon Radioisotopes; Deoxyglucose; Dose-Response Relationship, Radiation; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Male; Methionine; Neoplasm, Residual; Neoplasms, Experimental; Radiopharmaceuticals; Rats; Thymidine; Tomography, Emission-Computed; Tritium | 1997 |
[Positron emission tomography (PET) in diagnosis and therapy planning of malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Combined Modality Therapy; Deoxyglucose; Energy Metabolism; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Tomography, Emission-Computed; Treatment Outcome | 1997 |
A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1997 |
Identification of interleukin-2-induced complete response in metastatic renal cell carcinoma by FDG PET despite radiographic evidence suggesting persistent tumor.
Topics: Carcinoma, Renal Cell; Deoxyglucose; Diagnostic Errors; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Interleukin-2; Kidney Neoplasms; Middle Aged; Neoplasm, Residual; Pelvic Neoplasms; Radiography; Radiopharmaceuticals; Tomography, Emission-Computed | 1997 |
[Positron emission tomography detection of residual disease in a case of lung cancer].
Topics: Adult; Biomarkers, Tumor; Fluorodeoxyglucose F18; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Neoplasm, Residual; Radiopharmaceuticals; Tomography, Emission-Computed | 1997 |
FDG PET for detection and therapy control of metastatic germ cell tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Germinoma; Humans; Male; Neoplasm, Residual; Radiopharmaceuticals; Retrospective Studies; Seminoma; Testicular Neoplasms; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1998 |
Computed tomography, magnetic resonance imaging and positron emission tomography in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbon Radioisotopes; Carcinoma; Diagnosis, Differential; Fluorodeoxyglucose F18; Forecasting; Gastroscopy; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Methionine; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Radiopharmaceuticals; Remission Induction; Stomach Neoplasms; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1998 |
Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cohort Studies; Evaluation Studies as Topic; False Negative Reactions; False Positive Reactions; Fluorodeoxyglucose F18; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Middle Aged; Mouth Neoplasms; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm, Residual; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed; Tongue Neoplasms; Tonsillar Neoplasms | 1998 |
Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma.
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Surface Area; Body Weight; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1998 |
Comparative value of thallium and glucose SPECT imaging in childhood brain tumors.
Topics: Brain Neoplasms; Child; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Necrosis; Neoplasm Recurrence, Local; Neoplasm, Residual; Predictive Value of Tests; Radiation Injuries; Radiopharmaceuticals; Sensitivity and Specificity; Thallium Radioisotopes; Tomography, Emission-Computed, Single-Photon | 1998 |
Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling.
Topics: Adult; Diagnosis, Differential; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Germinoma; Humans; Male; Models, Biological; Necrosis; Neoplasm, Residual; Radiopharmaceuticals; Retroperitoneal Neoplasms; Teratoma; Tomography, Emission-Computed | 1999 |
Uses and limitations of FDG positron emission tomography in patients with head and neck cancer.
Topics: Carcinoma, Squamous Cell; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplasm, Residual; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 1999 |
Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography.
Topics: Biopsy; Carcinoma, Squamous Cell; Diagnosis, Differential; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed; Treatment Outcome | 1999 |
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diagnosis, Differential; Disease-Free Survival; Female; Fibrosis; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Predictive Value of Tests; Prognosis; Survival Analysis; Tissue Distribution; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1999 |
Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Gamma Cameras; Head; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neck; Neoplasm Recurrence, Local; Neoplasm, Residual; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 1999 |
FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm, Residual; Radiopharmaceuticals; Radiotherapy, High-Energy; Tomography, Emission-Computed | 1999 |
18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas.
Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2000 |
Reduced F-18 fluorodeoxyglucose uptake within marrow after external beam radiation.
Topics: Adult; Bone Marrow; Carcinoma, Squamous Cell; Cervical Vertebrae; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Neoplasm, Residual; Radiopharmaceuticals; Radiotherapy, High-Energy; Tomography, Emission-Computed | 2000 |
[Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in early detection of residual tumor in oro-pharyngeal-laryngeal carcinoma].
Topics: Biopsy; Carcinoma, Squamous Cell; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Laryngeal Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Oropharyngeal Neoplasms; Predictive Value of Tests; Tomography, Emission-Computed | 2000 |
Positron emission tomography in imaging spinal cord tumors.
Topics: Adolescent; Adult; Carbon Radioisotopes; Child; Child, Preschool; Combined Modality Therapy; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Infant; Magnetic Resonance Imaging; Male; Methionine; Middle Aged; Neoplasm, Residual; Radiotherapy, Adjuvant; Sensitivity and Specificity; Spinal Cord; Spinal Cord Neoplasms; Tomography, Emission-Computed | 2000 |
[Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
Topics: Adult; Aged; Aged, 80 and over; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Predictive Value of Tests; Radiopharmaceuticals; Recurrence; Reproducibility of Results; Retrospective Studies; Tomography, Emission-Computed; Tomography, X-Ray Computed; Ultrasonography | 2000 |
Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
Topics: Adult; Cohort Studies; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Radiopharmaceuticals; Recombinant Proteins; Recurrence; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Thyroid Hormones; Thyroid Neoplasms; Thyroidectomy; Thyrotropin; Tomography, Emission-Computed | 2001 |
Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Prognosis; Radiopharmaceuticals; Remission Induction; Survival Analysis; Tomography, Emission-Computed | 2001 |
Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease.
Topics: Adult; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Predictive Value of Tests; Tomography, Emission-Computed; Treatment Outcome | 2001 |
[Value of positron emission tomography in treatment of lymphoma patients].
Topics: Blood Glucose; Combined Modality Therapy; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Neoplasm, Residual; Sensitivity and Specificity; Survival Rate; Tomography, Emission-Computed; Treatment Outcome | 2001 |
Positron emission tomography and lymphoma therapy.
Topics: Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphoma; Neoplasm Staging; Neoplasm, Residual; Tomography, Emission-Computed; Treatment Outcome | 2001 |
Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Disease Progression; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm, Residual; Patient Selection; Prognosis; Radiopharmaceuticals; Recurrence; Retrospective Studies; Tomography, Emission-Computed; Treatment Outcome | 2001 |
18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma.
Topics: Biomarkers, Tumor; Calcitonin; Carcinoma, Medullary; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm, Residual; Radiopharmaceuticals; Thyroid Neoplasms; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2002 |
An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lung Neoplasms; Neoplasm Staging; Neoplasm, Residual; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed | 2002 |
[67-Gallium citrate gammagraphy in the study of lymphomas].
Topics: Citrates; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Gallium; Gallium Radioisotopes; Humans; Lymphoma; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2002 |
Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Topics: Adult; Biomarkers, Tumor; Fluorodeoxyglucose F18; Follow-Up Studies; Germinoma; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm, Residual; Prognosis; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2002 |